CRISPR-based drugs can theoretically manipulate any genetic target. In practice, however,
these drugs must enter the desired cell without eliciting an unwanted immune response, so …

In recent years, nanoparticles have evolved to a clinical modality to deliver diverse nucleic
acids. Rising interest in nanomedicines comes from proven safety and efficacy profiles …

Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left
ventricular wall thickness not solely explained by abnormal loading conditions. It is often …

Hypertrophic cardiomyopathy (HCM) is widely recognized as one of the most common
inheritable cardiac disorders. Since its initial description over 60 years ago, advances in …

Osteoarthritis (OA) is one of the most common degenerative joint diseases worldwide,
causing pain, disability, and decreased quality of life. The balance between regeneration …

Introduction: The development of patient-specific induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs) offers an opportunity to study genotype-phenotype correlation …

Cardiomyopathies are among the major triggers of heart failure, but their clinical and genetic
complexity have hampered our understanding of these disorders and delayed the …

Cardiovascular diseases are the most common cause of worldwide morbidity and mortality,
highlighting the necessity for advanced therapeutic strategies. Ca2+/calmodulin-dependent …

Hypertrophic cardiomyopathy (HCM) is the commonest genetic cardiomyopathy world-wide,
affecting approximately 1 in 500 individuals. Current therapeutic interventions comprise …

Gene therapy is defined by the introduction of new genes or the genetic modification of
existing genes and/or their regulatory portions via gene replacement and gene editing …